Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 2
1(25.0%)
4Total
N/A(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07390500Phase 2Recruiting

Assessment of the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia Disorder Control in Myopic Children ״DYMOND Study״

Role: lead

NCT04785690Not ApplicableCompleted

CURESIGHT BINOCULAR AMBLYOPIA TREATMENT STUDY

Role: lead

NCT05078099Not ApplicableCompleted

Eye-tracking Based Amblyopia Training

Role: lead

NCT05382676Unknown

Prospective Clinical Trials to Assess Performance and Safety of EyeSwift Pro

Role: lead

NCT05185076Not ApplicableUnknown

Treatment for Amblyopia Under Binocular Conditions Versus the Standard of Care, Monocular Deprivation Treatment

Role: lead

All 5 trials loaded